🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. TAEST16001 cells

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  2. TCR-T cells

    The First People's Hospital of Lianyungang

    Recurrent Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  3. TH-SC01(Umbilical cord mesenchymal stem cells)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Injury

    phase 1 mab active

    1 trial

  4. Target CD7 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  5. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  6. ThisCART22 cells injection

    The First People's Hospital of Lianyungang

    B Cell Malignancy

    phase 1 mab active

    1 trial

  7. ThisCART7 cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  8. Treatment of Respiratory Complications Associated with COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus (RSV) Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): open Phase IB Clinical Trial

    Lacuna Pharma Pty Ltd

    Respiratory viral disease, COVID-19, Influenza A, Metapneumovirus, Respiratory syncytial virus Infection

    phase 1 other active

    1 trial

  9. WT1-sensitized T cells

    Evidence Based Cataract Study Group

    Leukemia

    phase 1 mab completed

    1 trial

  10. YTS104 Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  11. ZFN modified T cells

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 mab completed

    1 trial

  12. anti CD19 CAR NK cells

    The First People's Hospital of Lianyungang

    Antisynthetase Syndrome

    phase 1 mab active

    1 trial

  13. anti-BCMA/CD70-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    CAR T Cell Therapy

    phase 1 mab active

    1 trial

  14. anti-CD19 allo-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed Adult ALL

    phase 1 mab active

    1 trial

  15. anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells

    The First People's Hospital of Lianyungang

    Relapsed/refractory Lymphoma

    phase 1 mab active

    1 trial

  16. anti-CD19-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  17. autologous ET1402L1-CART cells

    AEON Biopharma

    Hepatocellular Carcinoma

    phase 1 mab terminated

    1 trial

  18. autologous decidual-like NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Abortion, Habitual

    phase 1 mab active

    1 trial

  19. bronchial basal cells

    The First People's Hospital of Lianyungang

    Chronic Respiratory Disease

    phase 1 mab active

    1 trial

  20. clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial

  21. engineered autologous T cells

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 mab active

    1 trial

  22. fRPE cells

    The First People's Hospital of Lianyungang

    Age Related Macular Degeneration

    phase 1 small molecule active

    1 trial

  23. human HER2-targeted CAR-M cells

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 1 mab active

    1 trial

  24. iC9.GD2.CAR.IL-15 T-cells

    United Therapeutics Europe Ltd

    Neuroblastoma

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources